IL237369B - N-]2-(6-fluoro-h1-indol-3-yl)ethyl]-3-(2, 2, 3, 3- tetrafluoropropoxy) benzylamine in combination with an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease - Google Patents

N-]2-(6-fluoro-h1-indol-3-yl)ethyl]-3-(2, 2, 3, 3- tetrafluoropropoxy) benzylamine in combination with an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

Info

Publication number: IL237369B
Authority: IL; Israel
Prior art keywords: tetrafluoropropoxy; benzylamine; indol; fluoro; disease
Prior art date: 2012-09-09

Application number

IL237369A

Other languages

English (en)

Hebrew (he)

Other versions

IL237369A0 (en

Original Assignee

H Lundbeck As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-09

Filing date

2015-02-23

Publication date

2018-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL237369(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-02-23 Application filed by H Lundbeck As filed Critical H Lundbeck As

2015-04-30 Publication of IL237369A0 publication Critical patent/IL237369A0/en

2018-11-29 Publication of IL237369B publication Critical patent/IL237369B/en

Links

WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 title 2
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 title 1
239000000544 cholinesterase inhibitor Substances 0.000 title 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL237369A 2012-09-09 2015-02-23 N-]2-(6-fluoro-h1-indol-3-yl)ethyl]-3-(2, 2, 3, 3- tetrafluoropropoxy) benzylamine in combination with an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease IL237369B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261698664P	2012-09-09	2012-09-09
US201361782084P	2013-03-14	2013-03-14
PCT/EP2013/068516 WO2014037532A1 (en)	2012-09-09	2013-09-06	Methods of treating alzheimer's disease and pharmaceutical compositions thereof

Publications (2)

Publication Number	Publication Date
IL237369A0 IL237369A0 (en)	2015-04-30
IL237369B true IL237369B (en)	2018-11-29

Family

ID=49118521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL237369A IL237369B (en)	2012-09-09	2015-02-23	N-]2-(6-fluoro-h1-indol-3-yl)ethyl]-3-(2, 2, 3, 3- tetrafluoropropoxy) benzylamine in combination with an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

Country Status (33)

Country	Link
US (4)	US9375418B2 (2)
EP (1)	EP2892563B1 (2)
JP (2)	JP6693744B2 (2)
KR (2)	KR102342127B1 (2)
CN (1)	CN104619344A (2)
AP (1)	AP2015008306A0 (2)
AU (1)	AU2013311573B2 (2)
BR (1)	BR112015005117B1 (2)
CA (1)	CA2883751C (2)
CL (1)	CL2015000578A1 (2)
CY (1)	CY1121062T1 (2)
DK (1)	DK2892563T3 (2)
EA (1)	EA030448B1 (2)
ES (1)	ES2703630T3 (2)
GE (1)	GEP201706776B (2)
HR (1)	HRP20182069T1 (2)
IL (1)	IL237369B (2)
JO (1)	JO3459B1 (2)
LT (1)	LT2892563T (2)
MX (1)	MX368305B (2)
MY (1)	MY182539A (2)
NI (1)	NI201500031A (2)
NZ (1)	NZ630589A (2)
PL (1)	PL2892563T3 (2)
PT (1)	PT2892563T (2)
RS (1)	RS58104B1 (2)
RU (1)	RU2675786C2 (2)
SG (1)	SG11201501774QA (2)
SI (1)	SI2892563T1 (2)
SM (1)	SMT201800678T1 (2)
TN (1)	TN2015000076A1 (2)
TW (1)	TWI632909B (2)
WO (1)	WO2014037532A1 (2)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602004000260T2 (de)	2003-07-22	2006-08-24	Arena Pharmaceuticals, Inc., San Diego	Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
EP2508177A1 (en)	2007-12-12	2012-10-10	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JO3459B1 (ar)	2012-09-09	2020-07-05	H Lundbeck As	تركيبات صيدلانية لعلاج مرض الزهايمر
US9604982B2 (en)	2013-03-14	2017-03-28	Janssen Pharmaceutica Nv	P2X7 modulators
TWI644671B (zh)	2013-03-14	2018-12-21	比利時商健生藥品公司	Ｐ２ｘ７調節劑
US9040534B2 (en)	2013-03-14	2015-05-26	Janssen Pharmaceutica Nv	[1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar)	2013-03-14	2020-07-05	Janssen Pharmaceutica Nv	معدلات p2x7
ES2845473T3 (es)	2013-03-14	2021-07-26	Boehringer Ingelheim Int	(Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
JO3639B1 (ar)	2014-07-04	2020-08-27	H Lundbeck As	صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
EP3511331A1 (en)	2014-09-12	2019-07-17	Boehringer Ingelheim International GmbH	Spirocyclic inhibitors of cathepsin c
WO2016039977A1 (en)	2014-09-12	2016-03-17	Janssen Pharmaceutica Nv	P2x7 modulators
AU2015315693B2 (en)	2014-09-12	2020-01-16	Janssen Pharmaceutica Nv	P2X7 modulating n-acyl-triazolopyrazines
CN105175307A (zh) *	2014-11-18	2015-12-23	苏州晶云药物科技有限公司	Lu AE58054的盐酸盐晶型A及其制备方法和用途
JP2018515607A (ja) *	2015-05-07	2018-06-14	アクソファントサイエンシーズゲーエムベーハーＡｘｏｖａｎｔＳｃｉｅｎｃｅｓＧｍｂｈ	神経変性疾患を処置する組成物および方法
US10022355B2 (en)	2015-06-12	2018-07-17	Axovant Sciences Gmbh	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt)	2015-07-15	2018-09-04	Axovant Sciences Gmbh	resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
US10383849B2 (en) *	2016-04-26	2019-08-20	H. Lundbeck A/S	Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients
US10864191B2 (en)	2016-05-11	2020-12-15	H. Lundbeck A/S	5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
EA036347B1 (ru)	2016-05-18	2020-10-29	Сувен Лайф Сайенсиз Лимитед	Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы
CN106309436A (zh) *	2016-07-25	2017-01-11	宁波大学	可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) *	2017-04-13	2019-09-03	宁波大学	一种6-溴色胺衍生物及其制备方法和用途
BR112019001145A2 (pt) *	2017-05-24	2019-04-30	H. Lundbeck A/S	combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4
MY205440A (en)	2018-09-28	2024-10-21	Janssen Pharmaceutica Nv	Monoacylglycerol lipase modulators
KR20210069079A (ko)	2018-09-28	2021-06-10	얀센 파마슈티카 엔.브이.	모노아실글리세롤 리파아제 조절제
JP7697934B2 (ja)	2019-09-30	2025-06-24	ヤンセンファーマシューティカエヌ．ベー．	放射線標識されたｍｇｌｐｅｔリガンド
NL2024431B1 (en)	2019-12-11	2021-09-07	Sulfateq Bv	Compounds for treatment of alzheimer’s disease
BR112022019077A2 (pt)	2020-03-26	2022-12-27	Janssen Pharmaceutica Nv	Moduladores da monoacilglicerol lipase
EP3960174B1 (en)	2020-08-28	2024-10-30	Westfälische Wilhelms-Universität Münster	Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use
WO2025198622A1 (en) *	2024-03-22	2025-09-25	Queen Aaric	Magnesium and lidocaine composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3597149A (en)	1969-04-29	1971-08-03	Showa Denko Kk	Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en)	1972-04-28	1973-12-07	Aec Chimie Organique Bio	N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en)	1980-10-09	1982-04-19	Mitsui Toatsu Chem Inc	Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
DE3632329A1 (de)	1986-09-24	1988-03-31	Bayer Ag	Substituierte phenylsulfonamide
US5202336A (en)	1986-09-24	1993-04-13	Bayer Aktiengesellschaft	Antiflammatory quinolin methoxy phenylsulphonamides
SE9103745D0 (sv)	1991-12-18	1991-12-18	Wikstroem Haakan	Aryl-triflates and related compounds
DE69411143T2 (de)	1993-09-01	1998-10-22	Allelix Biopharma	Tryptamin analoge mit 5-ht1d selektivität
US5504101A (en)	1994-05-06	1996-04-02	Allelix Biopharmaceuticals, Inc.	5-HT-1D receptor ligands
AU752008B2 (en)	1997-09-29	2002-09-05	Aventis Pharmaceuticals Inc.	Aminoalkylphenol derivatives and related compounds
GB9820113D0 (en)	1998-09-15	1998-11-11	Merck Sharp & Dohme	Therapeutic agents
CA2353962C (en)	1998-12-11	2009-09-29	Virginia Commonwealth University	Selective 5-ht6 receptor ligands
CZ20012502A3 (cs)	1999-01-13	2002-03-13	Millennium Pharmaceuticals, Inc.	Funkcionalizované heterocykly jako modulátory chemokinových receptorů
US6750348B1 (en)	1999-03-24	2004-06-15	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
DK1859798T3 (en)	2001-03-29	2016-03-21	Lilly Co Eli	N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
RU2252936C2 (ru)	2002-12-05	2005-05-27	Институт физиологически активных веществ РАН	S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) *	2006-01-13	2008-01-20	Wyeth Corp	Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
JP2009541423A (ja)	2006-06-23	2009-11-26	ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ	コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
AR061637A1 (es)	2006-06-26	2008-09-10	Epix Delaware Inc	Composiciones y metodos de tratamiento de trastornos del snc
US20120184532A1 (en) *	2009-07-23	2012-07-19	Shire Llc	Galantamine amino acid and peptide prodrugs and uses thereof
TW201139370A (en)	2009-12-23	2011-11-16	Lundbeck & Co As H	Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar)	2012-09-09	2020-07-05	H Lundbeck As	تركيبات صيدلانية لعلاج مرض الزهايمر

2013
- 2013-08-21 JO JOP/2013/0248A patent/JO3459B1/ar active
- 2013-09-06 MX MX2015002879A patent/MX368305B/es active IP Right Grant
- 2013-09-06 CN CN201380046768.6A patent/CN104619344A/zh active Pending
- 2013-09-06 SI SI201331303T patent/SI2892563T1/sl unknown
- 2013-09-06 KR KR1020207034028A patent/KR102342127B1/ko active Active
- 2013-09-06 JP JP2015530420A patent/JP6693744B2/ja active Active
- 2013-09-06 EP EP13759195.4A patent/EP2892563B1/en active Active
- 2013-09-06 MY MYPI2015000575A patent/MY182539A/en unknown
- 2013-09-06 PL PL13759195T patent/PL2892563T3/pl unknown
- 2013-09-06 DK DK13759195.4T patent/DK2892563T3/en active
- 2013-09-06 GE GEAP201313752A patent/GEP201706776B/en unknown
- 2013-09-06 SM SM20180678T patent/SMT201800678T1/it unknown
- 2013-09-06 TW TW102132182A patent/TWI632909B/zh active
- 2013-09-06 RU RU2015107877A patent/RU2675786C2/ru active
- 2013-09-06 CA CA2883751A patent/CA2883751C/en active Active
- 2013-09-06 NZ NZ630589A patent/NZ630589A/en unknown
- 2013-09-06 BR BR112015005117-0A patent/BR112015005117B1/pt active IP Right Grant
- 2013-09-06 HR HRP20182069TT patent/HRP20182069T1/hr unknown
- 2013-09-06 KR KR1020157007345A patent/KR20150065680A/ko not_active Ceased
- 2013-09-06 PT PT13759195T patent/PT2892563T/pt unknown
- 2013-09-06 ES ES13759195T patent/ES2703630T3/es active Active
- 2013-09-06 SG SG11201501774QA patent/SG11201501774QA/en unknown
- 2013-09-06 WO PCT/EP2013/068516 patent/WO2014037532A1/en not_active Ceased
- 2013-09-06 AP AP2015008306A patent/AP2015008306A0/xx unknown
- 2013-09-06 AU AU2013311573A patent/AU2013311573B2/en active Active
- 2013-09-06 EA EA201590353A patent/EA030448B1/ru not_active IP Right Cessation
- 2013-09-06 LT LTEP13759195.4T patent/LT2892563T/lt unknown
- 2013-09-06 RS RS20181571A patent/RS58104B1/sr unknown
- 2013-09-09 US US14/021,033 patent/US9375418B2/en active Active
2015
- 2015-02-23 IL IL237369A patent/IL237369B/en active IP Right Grant
- 2015-03-02 TN TNP2015000076A patent/TN2015000076A1/fr unknown
- 2015-03-06 NI NI201500031A patent/NI201500031A/es unknown
- 2015-03-06 CL CL2015000578A patent/CL2015000578A1/es unknown
2016
- 2016-03-30 US US15/084,712 patent/US9687473B2/en active Active
- 2016-06-28 US US15/194,947 patent/US9789085B2/en active Active
2017
- 2017-09-06 US US15/696,880 patent/US10660878B2/en active Active
2018
- 2018-12-06 JP JP2018228631A patent/JP2019059760A/ja active Pending
- 2018-12-21 CY CY181101390T patent/CY1121062T1/el unknown

Also Published As

Publication number	Publication date
BR112015005117A2 (pt)	2017-07-04
SG11201501774QA (en)	2015-05-28
MX2015002879A (es)	2015-07-06
CA2883751A1 (en)	2014-03-13
US20160256437A1 (en)	2016-09-08
AU2013311573B2 (en)	2017-10-12
BR112015005117B1 (pt)	2022-06-21
WO2014037532A1 (en)	2014-03-13
AU2013311573A1 (en)	2015-03-12
RU2675786C2 (ru)	2018-12-25
TW201414474A (zh)	2014-04-16
US10660878B2 (en)	2020-05-26
CY1121062T1 (el)	2019-12-11
TN2015000076A1 (en)	2016-06-29
KR20150065680A (ko)	2015-06-15
US20180071254A1 (en)	2018-03-15
DK2892563T3 (en)	2019-01-21
RS58104B1 (sr)	2019-02-28
SI2892563T1 (sl)	2019-02-28
NI201500031A (es)	2016-02-15
JP2019059760A (ja)	2019-04-18
CA2883751C (en)	2020-11-24
US9687473B2 (en)	2017-06-27
JP6693744B2 (ja)	2020-05-13
AU2013311573A8 (en)	2015-03-19
HK1212217A1 (en)	2016-06-10
AP2015008306A0 (en)	2015-03-31
LT2892563T (lt)	2019-01-10
EP2892563B1 (en)	2018-11-14
MY182539A (en)	2021-01-25
CL2015000578A1 (es)	2015-05-15
US20160354343A1 (en)	2016-12-08
KR102342127B1 (ko)	2021-12-21
NZ630589A (en)	2015-12-24
KR20200137028A (ko)	2020-12-08
US9375418B2 (en)	2016-06-28
IL237369A0 (en)	2015-04-30
EA201590353A1 (ru)	2016-03-31
EA030448B1 (ru)	2018-08-31
US9789085B2 (en)	2017-10-17
RU2015107877A (ru)	2016-10-27
MX368305B (es)	2019-09-27
JO3459B1 (ar)	2020-07-05
GEP201706776B (en)	2017-11-27
HRP20182069T1 (hr)	2019-02-08
CN104619344A (zh)	2015-05-13
PL2892563T3 (pl)	2019-04-30
PT2892563T (pt)	2019-01-10
SMT201800678T1 (it)	2019-02-28
TWI632909B (zh)	2018-08-21
EP2892563A1 (en)	2015-07-15
US20140073681A1 (en)	2014-03-13
JP2015528471A (ja)	2015-09-28
ES2703630T3 (es)	2019-03-11

Legal Events

Date	Code	Title
2019-03-31	FF	Patent granted
2019-04-30	KB	Patent renewed
2019-08-29	KB	Patent renewed

Publication	Publication Date	Title
IL237369B (en)	2018-11-29	N-]2-(6-fluoro-h1-indol-3-yl)ethyl]-3-(2, 2, 3, 3- tetrafluoropropoxy) benzylamine in combination with an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
EP2707369A4 (en)	2014-12-10	COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
SMT202100259T1 (it)	2021-07-12	4'-fluoro-nucleosidi, 4'-fluoro-nucleotidi e loro analoghi per il trattamento di hcv s
EP2742155A4 (en)	2015-06-10	BIOMARKER FOR ALZHEIMER'S DISEASE AND / OR COGNITIVE LIGHT DISORDER, AND USE THEREOF
IL236054B (en)	2021-03-25	Compositions and methods for treating Crohn's disease and related conditions and infections
IN2015DN01156A (2)	2015-06-26
ZA201702799B (en)	2018-08-29	2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
SG11201403272YA (en)	2014-08-28	Compositions and methods for treating alzheimer's disease
IL223819A0 (en)	2013-03-05	3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
SI2739615T1 (sl)	2017-07-31	Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
ZA201402907B (en)	2015-04-29	Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
ZA201401678B (en)	2015-04-29	Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
MX359181B (es)	2018-09-17	Hidrolizado de colágeno y uso del mismo.
IL235429A0 (en)	2014-12-31	(r)-nifortal, its use in the treatment of infections and the preparation of (r) and (s)-nifortal
GB201302343D0 (en)	2013-03-27	Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
LT2872145T (lt)	2022-06-27	Sujungti benzazepinai tureto sindromui gydyti
ZA201402477B (en)	2015-12-23	Compounds for use in the treatment of alzheimer's disease
SG10201801200PA (en)	2018-04-27	An h3 receptor antagonist for use in the treatment of alzheimer's disease
FR2991406B1 (fr)	2014-06-20	Collier de serrage notamment pour le marquage de gibier
PL2768527T3 (pl)	2017-12-29	Wieloważna szczepionka przeciw CBV do zapobiegania lub leczenia cukrzycy typu 1
IL249428A0 (en)	2017-02-28	A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's
PL2593129T3 (pl)	2015-11-30	Nonapeptyd pat do stosowania w leczeniu choroby alzheimera
HK1195902A (en)	2014-11-28	Compositions and methods for treating alzheimer's disease
PL394761A1 (pl)	2011-12-05	Chromoforowa pochodna 4-amino-N-(2,6-dimetoksypirymidyn-4-ilo)benzenosulfonamidu i sposób jej wytwarzania
GB201101088D0 (en)	2011-03-09	L-carnosine and cinnamon extract for the treatment of Alzheimer's Disease